Advertisement
Table 2 Primary and secondary outcome measures follow up data
| 10 weeks | 6 month | |||||
|---|---|---|---|---|---|---|
| Measure | Intervention Mean (SD) | Control Mean (SD) | Adjusted difference* (95% CI) | Intervention Mean (SD) | Control Mean (SD) | Adjusted difference* (95% CI) |
| GDS | 12.23(5.22) n = 13 | 12.00 (4.26) n = 14 | 0.59 0.11(CI -2.59, 4.38) | 11.50 (6.66) n = 14 | 11.88 (4.88) n = 18 | 0.08 0.35 (-0.58,8.43) |
| CES-D | 18.27 (7.54) n = 11 | 15.27 (6.53) n = 15 | 0.94 0.01(CI -4.55, 4.90) | 15.28 (9.90) n = 14 | 14.44 (7.24) n = 18 | 0.55 0.11(-4.57, 8.33) |
| PGMS | 9.00 (3.61) n = 9 | 9.92 (3.15) n = 13 | 0.72-0.08 (CI -3.42, 2.42) | 9.57 (4.22) n = 14 | 9.11 (3.66) n = 18 | 0.48-0.13 (-4.06, 1.97) |
| HAP MAS | 72.36 (14.01) n = 14 | 65.47 (13.71) n = 15 | 0.07-0.28(CI -16.15, 0.70) | 67.07 (9.25) n = 14 | 67.11(14.10) n = 18 | 0.93 0.01 (-6.83, 7.41) |
| HAP AAS | 60.21 (19.77) n = 14 | 54.13 (18.45) n = 15 | 0.28-0.14(CI -14.69, 4.46) | 56.64 (14.59) n = 14 | 54.72 (18.83) n = 18 | 0.82 0.02 (-6.15, 7.65) |
| WHO QOL DOM 1** | 12.45 (2.00) n = 14 | 12.25 (1.40) n = 16 | 0.36-0.16 (CI -1.71, 0.64) | 13.39 (3.03) n = 14 | 12.42 (2.65) n = 18 | 0.05-0.28 (-3.19, 0.01) |
| WHO QOL DOM 2** | 12.67 (1.01) n = 14 | 13.04 (1.54) n = 16 | 0.66 0.09 (CI -0.81, 1.25) | 13.26 (1.69) n = 14 | 13.37 (2.03) n = 18 | 0.98-0.003 (-1.20, 1.18) |
| WHO QOL DOM 3** | 13.76 (3.28) n = 14 | 13.50 (2.10) n = 16 | 0.63-0.10 (CI -2.68, 1.65) | 13.90 (3.20) n = 14 | 13.44 (2.04) n = 18 | 0.59-0.10 (-2.55, 1.48) |
| WHO QOL DOM 4** | 14.97 (2.13) n = 14 | 14.66 (1.82) n = 16 | 0.18-0.19 (CI -1.86, 0.38) | 14.39 (2.42) n = 14 | 14.97 (2.24) n = 18 | 0.57-0.08 (-1.80, 1.02) |
| Self Efficacy | 14.23 (4.88) n = 13 | 12.36 (4.45) n = 14 | 0.45-0.16 (CI -5.43, 2.48) | 13.21 (5.05) n = 14 | 10.81 (3.83) n = 16 | 0.22-0.26 (-6.03, 1.46) |
| PASE | 115.76 (47.59) n = 11 | 97.84 (69.57) n = 15 | 0.26-0.19 (CI -63.80, 18.15) | 116.39 (49.13) n = 11 | 104.80 (69.07) n = 18 | 0.64-0.07 (-47.86, 30.19) |
